Top

Published in:

01-10-2017

Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors: Hikmat Abdel-Razeq, Asem Mansour

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2017

Abstract

Patients with cancer are at a much higher risk of thromboembolic events. Such events are occasionally associated with significant complications that can negatively affect patients’ quality of life. Thromboprophylaxis is widely practiced, but much of the emphasis is given for those admitted with acute medical illnesses or following major surgical procedures. However, a significant percentage of thrombotic events encountered in routine clinical practice are among ambulatory patients where current guidelines do not recommend routine thromboprophylaxis.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRefPubMed

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339–2346CrossRefPubMed

Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 11(2):223–233CrossRefPubMed

Khorana AA (2011) Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw 9(7):789–797CrossRefPubMed

Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost117(1):57–65

Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRefPubMed

Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7CrossRefPubMed

Carson JL, Kelley MA, Duff A et al (1992) The clinical course of pulmonary embolism. N Engl J Med 326:1240–1245CrossRefPubMed

Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264CrossRefPubMed

10.

Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490–493CrossRefPubMedPubMedCentral

11.

Sørensen HT, Mellemkj’r L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850CrossRefPubMed

12.

Khorona A, Francis C, Culakova E, Fisher R, Kuderer N, Lyman G (2009) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484–490CrossRef

13.

Prandoni P, Samama MM (2008) Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 141(5):587–597CrossRefPubMed

14.

Di Nisio M, Carrier M, Lyman GH, Khorana AA, Subcommittee on haemostasis and malignancy (2014) Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 12(10):1746–1749CrossRefPubMed

15.

Kakkar VV, Balibrea JL, Martı´nez-Gonza´lez J, Prandoni P (2010) CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 8(6):1223–1229CrossRefPubMed

16.

Lyman G, Bohlke K, Khorana A, Kuderer N, Lee A, Arcelus J et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:654–656CrossRefPubMedPubMedCentral

17.

Khan SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis. Chest 141(2 suppl):e195S–e226SCrossRef

18.

National Comprehensive Cancer Network (2017) Venous thromboembolic disease (version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed 15 July 2017

19.

Abdel-Razeq H, Albadainah F, Hijjawi S, Mansour A, Treish I (2011) Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax. J Thromb Thrombolysis 31:107–112CrossRefPubMed

20.

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634CrossRefPubMed

21.

Connors JM (2014) Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med 370(26):2515–2519CrossRefPubMed

22.

Oo TH (2016) Outpatient thromboprophylaxis with low-molecular weight heparin in solid tumors: where do we stand today? J Thromb Thrombolysis 41(3):539–540CrossRefPubMed

23.

Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488CrossRefPubMed

24.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L et al (2009) PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomized, placebo-controlled, double-blind study. Lancet Oncol 10(10):943–949CrossRefPubMed

25.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601–609CrossRefPubMed

26.

Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF et al (2012) TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159–165CrossRefPubMed

27.

Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48:1283–1292CrossRefPubMed

28.

Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S et al (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 33(18):2028–2034CrossRefPubMed

29.

Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A (2014) Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. Acta Oncol 53(9):1230–1237CrossRefPubMed

30.

Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A et al (1994) Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet 343:886–889CrossRef

31.

Tun NM, Guevara E, Oo TH (2016) Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 27(3):270–274CrossRefPubMed

32.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119:933–939CrossRefPubMed

33.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29:986–993CrossRef

34.

Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466–3473CrossRefPubMed

35.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907CrossRefPubMedPubMedCentral

36.

Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 5(Suppl 1):246–254CrossRefPubMed

37.

Wahrenbrock M, Borsig L, Le D, Varki N, Varki A (2003) Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112:853–862CrossRefPubMedPubMedCentral

38.

Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S et al (2008) Plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703–2708CrossRefPubMed

39.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116:5377–5382CrossRefPubMed

40.

Abdel-Razeq H, Mansour A, Saadeh S, Makoseh M, Ibrahim M, Ismael Y, Salam M, Abu Nasser M, Ibrahim A, Abufara A, Khirfan G (2017) The application of current proposed venous thromboembolism (VTE) risk assessment model (RAM) for ambulatory cancer patients. Clin Appl Thromb Hemost. doi: 10.1177/1076029617692880 PubMed

41.

Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T et al (2017) Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res 151:89–95CrossRefPubMed

42.

Van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR (2017) The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res 150:30–32CrossRefPubMed

43.

Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I, COMPASS–CAT Working Group (2017) A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS-cancer-associated thrombosis study. Oncologist. doi:10.1634/theoncologist.2016-0414 PubMed

44.

Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17(10):e452-e466CrossRefPubMed

45.

Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10(5):807–814CrossRefPubMed

46.

Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02048865?term=cancer&cond=Thromboses%2C+Venous&intr=Apixaban&draw=1&rank=9. Accessed 15 July 2017

47.

Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism. https://clinicaltrials.gov/ct2/show/NCT02555878?term=cancer&cond=Thromboses%2C+Venous&intr=Rivaroxaban&draw=2&rank=11. Accessed 15 July 2017

48.

Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW (2016) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 12:CD008500PubMed

Title: Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?
Authors: Hikmat Abdel-Razeq
Asem Mansour
Publication date: 01-10-2017
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-017-1542-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Involvement of superoxide generated by NADPH oxidase in the shedding of procoagulant vesicles from human monocytic cells exposed to bupivacaine

The effective systematic heparin pre-treatment on thrombus formation on pulmonary artery catheter tips during pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a randomized, double-blind study

Anti-coagulant activity of plants: mini review

Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina

Characterization of surface antigens of reticulated immature platelets

The use of natural language processing on pediatric diagnostic radiology reports in the electronic health record to identify deep venous thrombosis in children

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page